Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712426 · ClinicalTrials.gov registry record · Phase 3
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 553
- Enrollment target
NCT00712426: Clinical Trial Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00712426 is a Phase 3 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 553 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00712426, a Phase 3 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 553 participants
- Enrollment target
Study Summary
Huntington's disease (HD) is a slowly progressive disorder that devastates the lives of those affected and their families. There are no treatments that slow the progression of HD, only mildly effective symptomatic therapies are available.Creatine monohydrate is considered a nutritional supplement. The purpose of CREST-E is to test whether high-dose creatine can slow the progressive functional decline that occurs in persons 18 years or older with early clinical features of HD. The long-term safety, tolerability and effectiveness of up to 40 grams daily creatine compared to placebo is studied. A variety of biological processes are assessed for markers of disease activity or progression and creatine effects. Up to 50 active research centers globally will enroll 650 subjects.
Interventions
- DRUG Placebo
- DRUG Creatine Monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 553 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712426
The ClinicalTrials.gov registry entry for NCT00712426 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 553 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00712426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712426 about?
NCT00712426 is a clinical study titled "Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)". Huntington's disease (HD) is a slowly progressive disorder that devastates the lives of those affected and their families. There are no treatments that slow the progression of HD, only mildly effective symptomatic therapies are available.Creatine monohydrate is considered a nutritional supplement. T...
What is the current status of trial NCT00712426?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 553 participants. The study started on 2009-09. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00712426?
The interventions under investigation include: Placebo (DRUG), Creatine Monohydrate (DRUG).
Who is sponsoring clinical trial NCT00712426?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.